Download Files:
Products Details
Product Description
– FGFR-IN-10 is an orally active inhibitor of FGFR and Cytochrome P450 (CYPs). FGFR-IN-10 inhibits wide type and V564F mutant FGFR2 with IC50s of 104.1 nM and 43.6 nM, respectively. FGFR-IN-10 also inhibits CYPs with IC50s of 3.33 μM (CYP2C9), 18.75 μM (CYP2C19), 4.34 μM (CYP2CD6), and 0.69 μM (CYP3A4), respectively[1].
Web ID
– HY-148597
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C28H30FN9O2
References
– [1]Zhu Wei, et al. Heterocyclic compound serving as FGFR inhibitor and application thereof: World Intellectual Property Organization, WO2022206939. 2022-10-06.
CAS Number
– 2847092-41-3
Molecular Weight
– 543.60
SMILES
– FC(C=C1C2=CN=C(N=C2N3C[C@H](N([C@@H](C3)C)C(C=C)=O)C)NC4=CN(N=C4)C)=C(C=C1)OC5=NC=CC(C)=N5
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Cytochrome P450;FGFR
Isoform
– CYP2;CYP3;FGFR2
Pathway
– Metabolic Enzyme/Protease;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
